A Randomized, Phase II Study of INCB039110 or placebo in Combination with Docetaxel in Subjects with Previously Treated Stage IIIb, IV, or Recurrent NonSmall Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2018
Price : $35 *
At a glance
- Drugs Itacitinib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Incyte Corporation
- 05 Dec 2016 Status changed from active, no longer recruiting to discontinued.
- 10 May 2016 Trial status completed in Spain.
- 07 Mar 2016 Planned End Date changed from 1 Feb 2017 to 1 Jan 2019, according to ClinicalTrials.gov record.